It appears the US FDA may be able to influence generic drug sponsors' development priorities with its research projects, or at least pique their interest.
Data suggests that pre-ANDA meeting requests sometimes correlate with the number of internal and external research projects in the category, particularly when it comes to complex generics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?